As of May 28, 2025, Immunodiagnostic Systems Holdings PLC's estimated intrinsic value ranges from $90.70 to $226.77 per share, depending on the valuation methodology applied.
| Valuation Method | Fair Value (USD) | Implied Upside/Downside |
|---|---|---|
| Discounted Cash Flow (10Y) | $226.77 | -40.0% |
| Discounted Cash Flow (5Y) | $219.01 | -42.1% |
| Dividend Discount Model (Multi-Stage) | $163.07 | -56.9% |
| Dividend Discount Model (Stable) | $90.70 | -76.0% |
| Earnings Power Value | $130.29 | -65.5% |
Is Immunodiagnostic Systems Holdings PLC (IDH.L) undervalued or overvalued?
With the current market price at $378.00, the stock appears to be significantly overvalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Immunodiagnostic Systems Holdings PLC's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
| WACC Component | Low | High |
|---|---|---|
| Long-term bond rate | 2.9% | 3.4% |
| Equity market risk premium | 5.3% | 6.3% |
| Adjusted beta | 0.65 | 0.82 |
| Cost of equity | 6.4% | 9.2% |
| Cost of debt | 7.0% | 8.8% |
| Tax rate | 10.1% | 20.4% |
| Debt/Equity ratio | 0.03 | 0.03 |
| After-tax WACC | 6.4% | 9.1% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
| DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
|---|---|---|---|
| 5-Year Growth | $219 | $43M | 72.0% |
| 10-Year Growth | $227 | $45M | 55.2% |
| 5-Year EBITDA | $334 | $76M | 84.2% |
| 10-Year EBITDA | $329 | $74M | 73.0% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
| EPV Component | Value |
|---|---|
| Normalized Earnings | $1M |
| Discount Rate (WACC) | 9.1% - 6.4% |
| Enterprise Value | $14M - $20M |
| Net Debt | $(20)M |
| Equity Value | $35M - $40M |
| Outstanding Shares | 0M |
| Fair Value | $120 - $141 |
| Selected Fair Value | $130.29 |
| Metric | Value |
|---|---|
| Market Capitalization | $109M |
| Enterprise Value | $88M |
| Trailing P/E | 72.68 |
| Forward P/E | 47.06 |
| Trailing EV/EBITDA | 12.05 |
| Current Dividend Yield | 68.75% |
| Dividend Growth Rate (5Y) | -30.79% |
| Debt-to-Equity Ratio | 0.03 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
| Valuation Method | Weight | Weighted Value |
|---|---|---|
| Discounted Cash Flow (10Y) | 30% | $68.03 |
| Discounted Cash Flow (5Y) | 25% | $54.75 |
| Dividend Discount Model (Multi-Stage) | 20% | $32.61 |
| Dividend Discount Model (Stable) | 15% | $13.60 |
| Earnings Power Value | 10% | $13.03 |
| Weighted Average | 100% | $182.03 |
Based on our comprehensive valuation analysis, Immunodiagnostic Systems Holdings PLC's weighted average intrinsic value is $182.03, which is approximately 51.8% below the current market price of $378.00.
Key investment considerations:
Given these factors, we believe Immunodiagnostic Systems Holdings PLC is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.